Form 4: Cerus Director Timothy L. Moore Granted 60,000 Restricted Stock Units

Cerus Corporation's Director, Timothy L. Moore, has been granted 60,000 shares of common stock in the form of Restricted Stock Units (RSUs) as part of the company's 2024 Equity Incentive Plan.

Summary

• Timothy L. Moore, a Director of Cerus Corporation (CERS), acquired 60,000 shares of common stock on June 3, 2025, through a grant of Restricted Stock Units (RSUs).
• The RSUs were granted at a price of $0, indicating they are part of an equity compensation plan.
• Following this transaction, Mr. Moore's beneficial ownership of Cerus common stock stands at 205,073 shares.
• Each RSU represents a contingent right to receive one share of common stock.
• The RSUs are set to vest on the earlier of the first anniversary of the grant date (June 3, 2026) or the day prior to the next annual meeting of stockholders, contingent upon Mr. Moore's continuous service to the Issuer.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is generally a positive event as it aligns the director's financial interests with the long-term performance of the company and its shareholders. It is a standard compensation practice.

Positives

• The grant of Restricted Stock Units to Director Timothy L. Moore aligns his interests directly with those of the shareholders, as the value of his compensation is tied to the company's stock performance.
• The equity grant is part of the Issuer's 2024 Equity Incentive Plan, indicating a structured approach to executive and director compensation designed to incentivize long-term commitment and performance.

Future Outlook

The granted Restricted Stock Units are expected to vest on the earlier of the first anniversary of the grant date or the day prior to the next annual meeting of stockholders, contingent on the director's continuous service, leading to future issuance of common stock.

Industry Context

Equity grants, such as Restricted Stock Units, are a common form of compensation for directors and executives in the biotechnology and medical device industries, including companies like Cerus Corporation. This practice is widely adopted to attract and retain talent, and to align the interests of leadership with long-term shareholder value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a standard practice across the biotechnology and medical device sectors, aligning with compensation strategies observed in companies such as Haemonetics Corporation (HAE) or Terumo Corporation (TYO:4543), which frequently utilize equity-based incentives to retain key personnel and align interests.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is typical for director equity grants, ensuring continued engagement and service over a defined period, similar to practices seen at companies like Baxter International Inc. (BAX) or Becton, Dickinson and Company (BDX).

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially leading to more focused efforts on long-term value creation. However, it also represents potential future dilution upon vesting.
• Employees: While not directly impacting general employees, such grants are part of a broader compensation philosophy that can influence overall company culture and retention strategies for key personnel.

Next Steps

• The 60,000 Restricted Stock Units will vest on the earlier of June 3, 2026, or the day prior to the next annual meeting of stockholders, subject to Timothy L. Moore's continuous service.

Key Dates

Keywords

Cerus Corporation, CERS, Restricted Stock Units, RSU, Equity Incentive Plan, Insider Transaction, Director Compensation, SEC Form 4, Stock Grant, Beneficial Ownership